The Signs, Diagnosis and Treatment of Lyme Disease Discussed as Part of New, On-Demand Webinar Hosted by Industry-Leading Quidel Corporation
January 05 2022 - 9:00AM
Business Wire
An important public health webinar focused on the Bartonella
species, the bacterium that causes Bartonellosis, is now available
on demand at https://education.quidel.com/educational-categories.
Borrelia burgdorferi, the bacterium that causes Lyme disease, is
also discussed as a coinfection on this PACE-accredited webinar,
the third in a series hosted by Quidel Corporation (Nasdaq: QDEL)
in collaboration with Global Lyme Alliance.
Titled “The Diversity of Bartonellosis Manifestations and
Challenges to Treatment,” the webinar is conducted by Monica E.
Embers, Ph.D.,* associate professor of microbiology and immunology
and director of vector-borne disease research at Tulane National
Primate Research Center in Covington, Louisiana. Her research at
Tulane focuses on the effectiveness of antibiotics and other
therapeutics to eradicate Borrelia burgdorferi from the body while
also exploring the many avenues related to persistent Lyme
disease.
Dr. Embers currently serves on the 2021 Tick-Borne Disease
Working Group, which was established by Congress as part of the
21st Century Cures Act. Appointed to this position by the U.S.
Department of Health and Human Services, the Working Group serves
as a federal advisory committee to provide expertise and
recommendations regarding all tick-borne diseases, evaluate
tick-borne disease research priorities and help ensure coordination
between federal agencies. The primary function of the Working Group
is the development of a report of findings and recommendations
regarding the federal response to tick-borne disease prevention,
treatment and research, which it submits to Congress and the
Secretary of Health and Human Services.
On the webinar, Dr. Embers describes the possible clinical
presentations (signs and symptoms) of Bartonellosis; compares
Bartonellosis to Lyme borreliosis in terms of detection,
persistence and treatment; and identifies research efforts needed
to better diagnose and cure Bartonellosis. The timing and relevance
for the webinar is particularly important as Lyme disease is on the
rise to record numbers throughout the country and potentially
affected as many as 476,000 citizens in 2021.
Among those invited to view the webinar are physicians; allied
health professionals; health researchers; and representatives of
physician offices, laboratories, urgent care centers, patient
advocacy associations and others interested in the subject.
About Quidel Corporation
Quidel Corporation (Nasdaq: QDEL) is a leading manufacturer of
diagnostic solutions at the point of care, delivering a continuum
of rapid testing technologies that further improve the quality of
health care throughout the globe. An innovator for over 40 years in
the medical device industry, Quidel pioneered the first
point-of-care test for influenza in 1999 and was the first to
market a rapid SARS-CoV-2 antigen test in the U.S. Under trusted
brand names, Sofia®, Solana®, Lyra®, Triage® and QuickVue®,
Quidel’s comprehensive product portfolio includes tests for a wide
range of infectious diseases, cardiac and autoimmune biomarkers, as
well as a host of products to detect COVID-19. Quidel’s mission is
to provide patients with immediate and frequent access to highly
accurate, affordable testing for the good of our families, our
communities and the world. For more information about Quidel, visit
quidel.com.
*Dr. Embers receives an honorarium for conducting the webinar
sponsored by Quidel.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220105005461/en/
Jim Yeager 818-264-6812 (mobile) jim@breakwhitelight.com
QuidelOrtho (NASDAQ:QDEL)
Historical Stock Chart
From May 2024 to Jun 2024
QuidelOrtho (NASDAQ:QDEL)
Historical Stock Chart
From Jun 2023 to Jun 2024